Cardiosense is a digital health company based in Chicago that focuses on early detection and management of cardiac disease through advanced technology. The company has developed an AI platform that utilizes multimodal wearable technology to analyze physiological signals, enabling the identification of early changes in cardiovascular function.
The flagship product, the CardioTagâ„¢ Sensor, is a medical-grade wearable device that noninvasively measures seismocardiogram (SCG), photoplethysmogram (PPG), and electrocardiogram (ECG) signals. This device allows for comprehensive cardiac assessments in various care settings, providing high-quality data typically obtained through invasive methods. Cardiosense’s AI solutions include deep learning algorithms that convert raw sensor data into digital biomarkers, facilitating earlier detection of heart failure and other cardiac issues.
Targeting healthcare providers and systems, Cardiosense aims to enhance proactive cardiac care with tools for monitoring and personalized treatment. The company is particularly focused on congestive heart failure and has received FDA Breakthrough Device Designation for its early detection algorithm, highlighting its commitment to addressing critical needs in heart failure management.
